Filing Details

 

	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549
	SCHEDULE 13D

 

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

(Name of Issuer)

 

(Title of Class of Securities)

 

(CUSIP Number)

 

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017, and (iii) 1,057,769 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of warrants.

 

2

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017, and (iii) 1,057,769 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of warrants.

 

3

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017, and (iii) 1,057,769 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of warrants.

 

4

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, and (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017.

 

5

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, and (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017.

 

6

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, and (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017.

 

7

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, and (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017.

 

8

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, and (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017.

 

9

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017, (iii) 1,057,769 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of warrants, and (iv) 128,452 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of options.

 

10

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017, (iii) 1,057,769 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of warrants, and (iv) 128,452 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of options.

 

11

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017, (iii) 1,057,769 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of warrants, and (iv) 128,452 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of options.

 

12

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017, and (iii) 16,000 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of options.

 

13

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017, and (iii) 16,000 shares of Common Stock that the Reporting Person may acquire within 60 days upon the exercise of options.

 

14

 

 

(1) Calculation is based upon: (i) 9,395,920 shares of Common Stock outstanding as of November 8, 2017, as reported by the Issuer on a Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, and (ii) 2,958,094 total shares of Common Stock issued and sold on November 14, 2017 by the Issuer to a select group of institutional investors and strategic partners pursuant to purchase agreements as reported in the Issuers Current Report on Form 8-K, as filed with the Securities and Exchange Commission on November 17, 2017.

 

15

 

 

SCHEDULE 13D

 

Item 1.         Security and Issuer

 

This Amendment No. 1 to Schedule 13D relates to Common Stock, par value $0.001 per share (the Common Stock), of Leap Therapeutics, Inc., a Delaware corporation (the Issuer or the Company or Issuer).  The address of the principal executive offices of the Issuer is 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts 02141.

 

Item 2.         Identity and Background

 

(a) This Amendment No. 1 to Schedule 13D is being filed on behalf of:

 

·                  (i) HealthCare Ventures IX, L.P., a Delaware limited partnership (HCV IX);

·                  (ii) HealthCare Partners IX, L.P., a Delaware limited partnership, and the general partner of HCV IX (HCP IX);

·                  (iii) HealthCare Partners IX, LLC, a Delaware limited liability company, and the general partner of HCP IX (HCP IX LLC, and together with HCV IX and HCP IX, HealthCare IX);

·                  (iv) HealthCare Ventures VIII, L.P., a Delaware limited partnership (HCV VIII);

·                  (v) HealthCare Partners VIII, L.P., a Delaware limited partnership, and the general partner of HCV VIII (HCP VIII);

·                  (vi) HealthCare Partners VIII, LLC, a Delaware limited liability company, and the general partner of HCP VIII (HCP VIII LLC, and together with HCV VIII and HCP VIII, HealthCare VIII);

·                  (vii) HealthCare Ventures Strategic Fund, L.P., a Delaware limited partnership (Ventures Strategic);

·                  (viii) HealthCare Strategic Partners, LLC, a Delaware limited liability company, and the general partner of Ventures Strategic (Strategic LLC, and together with Ventures Strategic, HealthCare Strategic);

·                  (ix) Christopher Mirabelli (Dr. Mirabelli), a managing director of each of HCP IX LLC, HCP VIII LLC and Strategic LLC;

·                  (x) Augustine Lawlor (Mr. Lawlor), a managing director of each of HCP IX LLC, HCP VIII LLC and Strategic LLC;

·                  (xi) Douglas E. Onsi (Mr. Onsi), a managing director of each of HCP IX LLC and Strategic LLC;

·                  (xii) James H. Cavanaugh (Dr. Cavanaugh), a managing director of HCP VIII LLC;

·                  (xii) John W. Littlechild (Mr. Littlechild), a managing director of HCP VIII LLC; and

·                  (xiv) Harold Werner (Mr. Werner), a managing director of HCP VIII LLC.

 

The persons and entities referred to in items (i)-(xiv) hereof may be collectively referred to herein as the Reporting Persons.

 

Dr. Mirabelli, Mr. Lawlor, Dr. Cavanaugh, Mr. Littlechild and Mr. Werner, as managing directors of HCP VIII LLC, exercise voting and investment control over any securities held by HCP VIII and HCV VIII. The number of shares of Common Stock held for the accounts of HCP VIII and HCV VIII is reported on the cover pages.

 

16

 

 

Mr. Mirabelli, Mr. Lawlor and Mr. Onsi, as managing directors of HCP IX LLC, exercise voting and investment control over any securities held by HCP IX and HCV IX. The number of shares of Common Stock held for the accounts of HCP IX and HCV IX is reported on the cover pages.

 

Mr. Mirabelli, Mr. Lawlor and Mr. Onsi, as managing directors of Strategic LLC, exercise voting and investment control over any securities held by Ventures Strategic. The number of shares of Common Stock held for the accounts of Ventures Strategic is reported on the cover pages.

 

(b) The business address of each of the Reporting Persons is  47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts  02141.

 

(c) Each of HCV VIII, HCP VIII, HCP VIII LLC, HCV IX, HCP IX, HCP IX LLC, Ventures Strategic and Strategic LLC is a private investment vehicle.

 

Each of Dr. Mirabelli, Mr. Lawlor and Mr. Onsi serves as a managing director of each of HCP IX LLC and Strategic LLC, and, in those capacities, the principal occupation of each of Dr. Mirabelli, Mr. Lawlor and Mr. Onsi is investment management.  Dr. Mirabelli is also the Chief Executive Officer, President and Chairman of the Board of Directors of the Issuer. Mr. Onsi is also the Chief Financial Officer, General Counsel, Treasurer and Secretary of the Issuer. Mr. Lawlor is also the Chief Operating Officer of the Issuer.

 

Each of Mr. Mirabelli, Mr. Lawlor, Dr. Cavanaugh, Mr. Littlechild and Mr. Werner serves as a managing director of HCP VIII LLC, and, in that capacity, the principal occupation of each of Dr. Mirabelli, Mr. Lawlor, Dr. Cavanaugh, Mr. Littlechild and Mr. Werner is investment management.  Dr. Cavanaugh and Mr. Littlechild are directors of the Issuer.

 

(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or State securities laws or finding any violation with respect to such laws.

 

(f) See Item 6 of the respective cover page of each Reporting Person.

 

Item 3.         Source and Amount of Funds or Other Consideration

 

On January 23, 2017, the Issuer closed a merger transaction (the Merger) with Macrocure Ltd. (previously NASDAQ: MCUR) (Macrocure) whereby a wholly owned subsidiary of Leap merged with and into Macrocure and Macrocure became a wholly owned subsidiary of Leap (the Merger). Pursuant to the merger, each holder of ordinary shares, par value NIS 0.01 per share, of Macrocure, received common stock of the Issuer pursuant to an established exchange ratio, plus cash in lieu of fractional shares. The Merger was described further in the final prospectus, dated November 23, 2016, filed by the Issuer with the Securities and Exchange Commission, or SEC, on November 23, 2016 pursuant to Rule 424(b)(3) under the Securities Act of 1933, as amended (the Prospectus). The Agreement and Plan of Merger dated as of August 29, 2016, among the Issuer, M-CO Merger Sub Ltd., or Merger Sub, and Macrocure was attached as Annex A to the Prospectus (the Merger Agreement). Stockholders of the Issuer did not acquire any shares pursuant to the merger agreement or otherwise in connection with the transactions contemplated by the Merger Agreement.

 

17

 

 

Pursuant to the terms of the Merger Agreement, immediately prior to the consummation of the Merger, in connection with the Issuer filing an amended and restated certificate of incorporation, each issued and outstanding share of Issuer preferred stock and each outstanding Issuer convertible promissory note converted into shares of Issuer common stock and share of Issuer common stock issued and outstanding immediately prior to the effective time of the Merger was reclassified and changed into a number of shares of Leap common stock at an agreed upon ratio that brought the Issuers fully diluted capitalization to, at the time of the merger, approximately 6,500,000 shares of common stock.

 

In addition, immediately prior to the consummation of the Merger, the Issuer and HCV IX entered into a Subscription Agreement (the Subscription Agreement) pursuant to which HCV IX invested $10.0 million into the Issuer by purchasing 1,010,225 shares of the Issuers common stock at a purchase price per share of $9.90 (the Equity Investment). The Equity Investment was exempted from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving any public offering.

 

Immediately prior to the conversion, reclassification and Equity Investment, in addition to outstanding notes, (i) HCV VIII held 16,785,000 shares of Series B Preferred Stock of the Issuer, (ii) HCV IX held 2,150,000 shares of Series B Preferred Stock and 11,781,984 shares of Series C Preferred Stock, and (iii) Ventures Strategic held 2,565,000 shares of Series B Preferred Stock. Immediately after and as a result of such conversion, reclassification and the Equity Investment, HCV VIII held 2,618,406 shares of the Issuers common stock, HCV IX held 2,515,607 shares of the Issuers common stock, and Ventures Strategic held 343,889 shares of the Issuers Common Stock.

 

Christopher K. Mirabelli, James H. Cavanaugh, John W. Littlechild, Harold Werner and Augustine Lawlor (collectively, the HCV VIII Directors) are the Managing Directors of HCP VIII LLC, which is the General Partner of HCP VIII, which is the General Partner of HCV VIII. Each of the HCV VIII Directors, HCP VIII LLC and HCP VIII beneficially own and share voting and dispositive power with respect to all of the securities owned by HCV VIII. Each of the HCV VIII Directors disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

 

Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the HCV IX Directors) are the Managing Directors of HCP LLC, which is the General Partner of HCP IX, which is the General Partner of HCV IX. Each of the HCV IX Directors, HCP IX LLC and HCP IX beneficially own and share voting and dispositive power with respect to all of the securities owned by HCV IX. Each of the HCV IX Directors disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

 

Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the HCSP  Directors) are the Managing Directors of Strategic LLC, which is the General Partner of Ventures Strategic. Each of the HCSP Directors, and Strategic LLC beneficially own and share voting and dispositive power with respect to all of the securities owned by Ventures Strategic. Each of the HCSP Directors disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.

 

In connection with the consummation of the Merger, each of Dr. Mirabelli, Mr. Lawlor, Mr. Onsi, Dr. Cavanaugh and Mr. Littlechild were granted options to purchase shares of Common Stock, subject to terms set forth in stock option agreements. As of the date hereof, in accordance with such agreements,

 

18

 

 

128,452 shares of Common Stock have vested, or will vest within 60 days, for each of Dr. Mirabelli, Mr. Lawlor and Mr. Onsi, and 16,000 shares of Common Stock have vested, or will vest within 60 days, for each of Dr. Cavanaugh and Mr. Littlechild.

 

On November 14, 2017, the Issuer entered into purchase agreements to issue and sell in the aggregate 2,958,094 shares of its Common Stock and warrants to purchase up to 2,958,094 of Common Stock at a price of $6.085 per unit in a private placement with a select group of institutional investors and strategic partners for total gross proceeds of $18.0 million. The exercise price of the warrants is $6.085. HCV IX purchased, pursuant to a purchase agreement, 1,057,769 shares of Common Stock and warrants to purchase up to 1,057,769 shares of Common Stock. Such warrants are immediately exercisable, but certain anti-dilution provisions of the warrants were subject to stockholder approval which were subsequently approved at a Stockholders meeting held on January 12, 2018. As a result, each of HCV IX, HCP IX, HCP IX LLC, Dr. Mirabelli, Mr. Lawlor and Mr. Onsi acquired, directly or indirectly, an aggregate of 1,057,769 shares of the Common Stock and warrants to purchase 1,057,769 shares of Common Stock.

 

The working capital of HCV IX was the source of the funds for the purchase of the HCV IX Shares.  No part of the purchase price of the HCV IX was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the HCV IX Shares.

 

Item 4.         Purpose of Transaction

 

The Reporting Persons acquired and hold the Common Stock reported herein for investment purposes.

 

Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Reporting Persons may acquire additional shares of Common Stock and other securities of the Company from time to time or may dispose of any or all of such shares or other securities held by them from time to time.

 

At the present time, other than as set forth above, the Reporting Persons do not have any plans or proposals that relate or would result in:

 

(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;

 

(b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;

 

(c) A sale or transfer of a material amount of assets of the issuer or any of its subsidiaries;

 

(d) Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

 

(e) Any material change in the present capitalization or dividend policy of the issuer;

 

(f) Any other material change in the issuers business or corporate structure, including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

 

19

 

 

(g) Changes in the issuers charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

 

(h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

 

(i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the Act; or

 

(j) Any action similar to any of those enumerated above.

 

Item 5.         Interest in Securities of the Issuer

 

(a)

 

HCV VIII is the record owner of the HCV VIII shares.  As the general partner of HCV VIII, HCP VIII may be deemed to beneficially own the HCV VIII shares.  As the general partner of HCP VIII, HCP VIII LLC may also be deemed to beneficially own the HCV VIII shares.  As the managing directors of HCP VIII LLC, each of Dr. Mirabelli, Mr. Lawlor, Dr. Cavanaugh, Mr. Littlechild and Mr. Werner may be deemed to own beneficially the HCV IX Shares. Each Reporting Person disclaims beneficial ownership of the HCV IX shares other than those shares which such person owns of record.

 

HCV IX is the record owner of the HCV IX Shares.  As the general partner of HCV IX, HCP IX may be deemed to beneficially own the HCV IX shares.  As the general partner of HCP IX, HCP IX LLC may also be deemed to beneficially own the HCV IX shares.  As the managing directors of HCP IX LLC, each of Dr. Mirabelli, Mr. Lawlor and Mr. Onsi may be deemed to own beneficially the HCV IX Shares. Each Reporting Person disclaims beneficial ownership of the HCV IX shares other than those shares which such person owns of record.

 

Ventures Strategic is the record owner of the Ventures Strategic shares.  As the general partner of Venture Strategic , Strategic LLC may be deemed to beneficially own the Ventures Strategic shares.  As the managing directors of Strategic LLC, each of Dr. Mirabelli, Mr. Lawlor and Mr. Onsi may be deemed to own beneficially the Strategic LLC shares. Each Reporting Person disclaims beneficial ownership of the Strategic LLC shares other than those shares which such person owns of record.

 

The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Persons cover sheet.  Such percentage calculations herein are based upon (i) the statement in the Companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 13, 2017, that there were 9,395,920 shares of the registrants common stock, par value $0.001 per share, outstanding as of November 8, 2017, and (ii) a statement in the Companys Current Report on Form 8-K that On November 14, 2017, the Issuer entered into purchase agreements to issue and sell 2,958,094 shares of its Common Stock. Such beneficial ownership calculations also take into account any warrants or options that may be exercised currently or within 60 days.

 

20

 

 

In connection with the consummation of the Merger, each of Dr. Mirabelli, Mr. Lawlor, Mr. Onsi, Dr. Cavanaugh and Mr. Littlechild were granted options to purchase shares of Common Stock, subject to terms set forth in stock option agreements. As of the date hereof, in accordance with such agreements, 128,452 shares of Common Stock have vested, or will vest within 60 days, for each of Dr. Mirabelli, Mr. Lawlor and Mr. Onsi, and 16,000 shares of Common Stock have vested, or will vest within 60 days, for each of Dr. Cavanaugh and Mr. Littlechild.

 

See Items 7-11 of each Reporting Persons cover page, and Item 2 above for information regarding amounts and percentages of beneficial ownership for each Reporting Person.

 

(b)

 

(i) sole power to vote or to direct the vote: See line 7 of cover sheets.

 

(ii) shared power to vote or to direct the vote: See line 8 of cover sheets.

 

(iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets.

 

(iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.

 

See Item 2 for more information with respect to each person with whom the power to vote or to direct the vote or to dispose or direct the disposition is shared.

 

(c) On November 14, 2017, the Issuer entered into purchase agreements to issue and sell 2,958,094 shares of its common stock, par value $0.001 per share (the Common Stock) and warrants to purchase 2,958,094 of Common Stock at a price of $6.085 per unit in a private placement with a select group of institutional investors and strategic partners for total gross proceeds of $18.0 million. HCV IX purchased 1,057,762 shares of Common Stock and warrants to purchase 1,057,762 shares of Common Stock. Such warrants are immediately exercisable, but certain anti-dilution provisions of the warrants were subject to stockholder approval which were subsequently approved at a Stockholders meeting held on January 12, 2018.

 

(d)  See Items 7-11 of the cover pages and Item 2 above.

 

(e)  Not applicable.

 

Item 6.         Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

See Item 3 above, which is hereby incorporated herein.

 

On January 23, 2017, the Issuer entered into a registration rights agreement certain holders of Common Stock (the RRA), pursuant to which the holders were granted certain demand and piggyback registration rights with respect to any and all shares of Common Stock held or acquired by the holders on or after the date of the RRA.  In connection with the PIPE, the holders of at least a majority of the currently outstanding securities of the Issuer that were entitled to registration rights under the RRA entered into a waiver agreement, whereby the holders agreed to waive any and all demand or piggyback registration rights and related obligations of the Issuer arising from the RRA.

 

The Warrants issued in connection with the PIPE include full ratchet anti-dilution protection provisions. Therefore, the Company held a special meeting of stockholders at which meeting the stockholders approved the anti-dilution protection provisions.

 

21

 

 

In connection with the PIPE, each Reporting Person is subject to a lock-up pursuant to which each such Reporting Person has generally agreed, subject to certain exceptions, not to dispose of or hedge any shares of Common Stock or securities convertible into or exchangeable for shares of Common Stock, for a period of 60 days after the effective date of the Registration Statement filed with the SEC for the resale registration of the Common Stock issued in the November 14, 2017, offering and the shares of Common Stock issuable upon exercise of the warrants sold in the offering.

 

Item 7.         Material to Be Filed as Exhibits

 

Exhibit 99.1                              Joint Filing Agreement, by and among the Reporting Persons (incorporated by reference to Exhibit 99.1 to Schedule 13D (File No. 005-90188) filed with the SEC on November 21, 2017).

 

Exhibit 99.2                              Form of Purchase Agreement, dated as of November 14, 2017, by and among Leap Therapeutics, Inc. and the purchasers identified on the schedule thereto (incorporated by reference to Exhibit 99.2 to Schedule 13D (File No. 005-90188) filed with the SEC on November 21, 2017).

 

Exhibit 99.3                              Form of Warrant, dated as of November 14, 2017 by and among Leap Therapeutics, Inc. and the purchasers identified on the schedule thereto (incorporated by reference to Exhibit 99.3 to Schedule 13D (File No. 005-90188) filed with the SEC on November 21, 2017).

 

Exhibit 99.4                              Voting Agreement, dated as of November 14, 2017 by and among Leap Therapeutics, Inc., HealthCare Ventures VIII, L.P., HealthCare Ventures IX, L.P. and HealthCare Ventures Strategic Fund, L.P. (incorporated by reference to Exhibit 99.4 to Schedule 13D (File No. 005-90188) filed with the SEC on November 21, 2017).

 

Exhibit 99.5                              Lock-up Agreement, dated as of November 14, 2017 from each of the individuals identified on the schedule thereto (incorporated by reference to Exhibit 99.5 to Schedule 13D (File No. 005-90188) filed with the SEC on November 21, 2017).

 

Exhibit 99.5                              Power of Attorney, dated as of November 4, 2013 from each of Christopher Mirabelli, John Littlechild, Augustine Lawlor, Harold Werner and Douglas Onsi in favor of Jeffrey Steinbert (incorporated by reference to Exhibit 24.3 to Form 3 (File No. 001-36208) filed with the SEC on December 11, 2013).

 

22

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:         February 14, 2018
	HEALTHCARE VENTURES VIII, L.P.
	By: HealthCare Partners VIII, L.P., its general partner
	By: HealthCare Partners VIII, LLC, its general partner
		By:	/s/ Jeffrey Steinberg
		Name:	Jeffrey Steinberg
		Title:	Administrative Partner
	HEALTHCARE PARTNERS VIII, L.P.
	By: HealthCare Partners VIII, LLC, its general partner
		By:	/s/ Jeffrey Steinberg
		Name:	Jeffrey Steinberg
		Title:	Administrative Partner
	HEALTHCARE PARTNERS VIII, LLC
		By:	/s/ Jeffrey Steinberg
		Name:	Jeffrey Steinberg
		Title:	Administrative Partner

 

23

 

 

	HEALTHCARE VENTURES IX, L.P.
	By: HealthCare Partners IX, L.P., its general partner
	By: HealthCare Partners IX, LLC, its general partner
		By:	/s/ Jeffrey Steinberg
		Name:	Jeffrey Steinberg
		Title:	Administrative Partner
	HEALTHCARE PARTNERS IX, L.P.
	By: HealthCare Partners IX, LLC, its general partner
		By:	/s/ Jeffrey Steinberg
		Name:	Jeffrey Steinberg
		Title:	Administrative Partner
	HEALTHCARE PARTNERS IX, LLC
		By:	/s/ Jeffrey Steinberg
		Name:	Jeffrey Steinberg
		Title:	Administrative Partner
	HEALTHCARE VENTURES STRATEGIC FUND, L.P.
	By: HealthCare Strategic Partners, LLC, its general partner
		By:	/s/ Jeffrey Steinberg
		Name:	Jeffrey Steinberg
		Title:	Administrative Partner

 

24

 

 

	HEALTHCARE STRATEGIC PARTNERS, LLC
		By:	/s/ Jeffrey Steinberg
		Name:	Jeffrey Steinberg
		Title:	Administrative Partner
	CHRISTOPHER K. MIRABELLI, Ph.D.
		By:	/s/ Jeffrey Steinberg, Attorney-in-fact
		Name:	Christopher K. Mirabelli, Ph.D.
	AUGUSTINE LAWLOR
		By:	/s/ Jeffrey Steinberg, Attorney-in-fact
		Name:	Augustine Lawlor
	DOUGLAS E. ONSI
		By:	/s/ Jeffrey Steinberg, Attorney-in-fact
		Name:	Douglas E. Onsi
	JAMES H. CAVANAUGH
		By:	/s/ Jeffrey Steinberg, Attorney-in-fact
		Name:	James H. Cavanaugh
	JOHN W. LITTLECHILD
		By:	/s/ Jeffrey Steinberg, Attorney-in-fact
		Name:	John W. Littlechild

 

25

 

 

	HAROLD WERNER
		By:	/s/ Jeffrey Steinberg, Attorney-in-fact
		Name:	Harold Werner

 

26